Evolution of the Average Target: Bio-Rad Laboratories, Inc.

Evolution of the Target Price: Bio-Rad Laboratories, Inc.

Changes in Analyst Recommendations: Bio-Rad Laboratories, Inc.

576351d8ca.ib0WauNDo_icXjDTNoJeiDnxrcnXSlNV8BVwT0peyZk.6pBzOrIHk7fkH2WcdegrxlSA3qSkGQUQpmECKg9nhs3FxEkpiQ_Ivs8mcQ~67888a3e8997864e237fe70cfa5d59b4
07/08 RBC Adjusts PT on Bio-Rad Laboratories to $390 From $370, Maintains Outperform Rating MT
05/08 RBC Adjusts Price Target on Bio-Rad Laboratories to $370 From $320, Maintains Outperform Rating MT
15/05 Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says MT
07/04 Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $300 From $375 MT
13/02 UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating MT
30/25/30 Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair… Zonebourse
03/25/03 RBC Raises Price Target on Bio-Rad Laboratories to $437 From $409, Keeps Outperform Rating MT
01/25/01 UBS Adjusts Price Target on Bio-Rad Laboratories to $325 From $310, Maintains Buy Rating MT
01/25/01 RBC Raises Price Target on Bio-Rad Laboratories to $409 From $387, Keeps Outperform Rating MT
01/25/01 RBC Raises Price Target on Bio-Rad Laboratories to $387 From $381, Keeps Outperform Rating MT
02/25/02 UBS Adjusts Price Target on Bio-Rad Laboratories to $310 From $355, Maintains Buy Rating MT
02/25/02 RBC Cuts Price Target on Bio-Rad Laboratories to $392 From $409, Keeps Outperform Rating MT
08/25/08 RBC Cuts Price Target on Bio-Rad Laboratories to $409 From $430, Keeps Outperform Rating MT
14/25/14 UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating MT
14/25/14 RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating MT
04/25/04 RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating MT
09/24/09 RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating MT
31/24/31 UBS Adjusts Price Target on Bio-Rad Laboratories to $390 From $400, Maintains Buy Rating MT
01/24/01 Citigroup Upgrades Bio-Rad Laboratories to Buy From Neutral, Adjusts Price Target to $400 From $350 MT
13/24/13 RBC Raises Price Target on Bio-Rad Laboratories to $446 From $401, Keeps Outperform Rating MT
28/24/28 Wells Fargo Initiates Bio-Rad Laboratories at Equalweight With $340 Price Target MT
02/24/02 Citigroup Adjusts Price Target on Bio-Rad Laboratories to $350 From $300 MT
02/24/02 UBS Adjusts Price Target on Bio-Rad Laboratories to $400 From $385, Maintains Buy Rating MT
02/24/02 RBC Trims Price Target on Bio-Rad Laboratories to $401 From $402, Keeps Outperform Rating MT
24/24/24 RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-14.79%
+8.92%
+9.03%
+14.12%
+4.02%
+24.66%
+3.36%
+27.36%
+18.65%
+24.53%
Average +11.99%
Weighted average by Cap. +11.65%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
386.12USD
Average target price
329.00USD
Spread / Average Target
-14.79%
High Price Target
390.00USD
Spread / Highest target
+1.00%
Low Price Target
280.00USD
Spread / Lowest Target
-27.48%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. BIO Stock
  4. Consensus Bio-Rad Laboratories, Inc.